SCEMBLIX Drug Patent Profile
✉ Email this page to a colleague
When do Scemblix patents expire, and when can generic versions of Scemblix launch?
Scemblix is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has eighty-four patent family members in forty-nine countries.
The generic ingredient in SCEMBLIX is asciminib hydrochloride. One supplier is listed for this compound. Additional details are available on the asciminib hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Scemblix
Scemblix will be eligible for patent challenges on October 29, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 14, 2040. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SCEMBLIX?
- What are the global sales for SCEMBLIX?
- What is Average Wholesale Price for SCEMBLIX?
Summary for SCEMBLIX
| International Patents: | 84 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Patent Applications: | 1 |
| Drug Prices: | Drug price information for SCEMBLIX |
| What excipients (inactive ingredients) are in SCEMBLIX? | SCEMBLIX excipients list |
| DailyMed Link: | SCEMBLIX at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SCEMBLIX
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for SCEMBLIX
SCEMBLIX is protected by two US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SCEMBLIX is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SCEMBLIX
Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(- 1H-pyrazol-5-yl)pyridine-3-carboxamide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
FDA Regulatory Exclusivity protecting SCEMBLIX
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP), PREVIOUSLY TREATED WITH TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP) WITH THE T315I MUTATION
Exclusivity Expiration: ⤷ Sign Up
FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-001 | Oct 29, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-002 | Oct 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-001 | Oct 29, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-003 | Apr 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-002 | Oct 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-003 | Apr 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SCEMBLIX
When does loss-of-exclusivity occur for SCEMBLIX?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 20276701
Patent: Crystalline forms of N-(4-(chlorodifluoromethoxy)phenyl)-6-((3R)-3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2021022712
Patent: Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 39812
Patent: FORMES CRISTALLINES DE N-[4- (CHLORODIFLUOROMETHOXY) PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE (CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 21003011
Patent: Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida
Estimated Expiration: ⤷ Sign Up
China
Patent: 4144232
Patent: N-[4-(氯二氟甲氧基)苯基]-6-[(3R)-3-羟基吡咯烷-1-基]-5-(1H-吡唑-5-基)吡啶-3-甲酰胺的结晶形式 (Crystalline forms of n-[4-(chlorodifluoromethoxy) phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl) pyridine-3-carboxamide)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 69117
Patent: FORMES CRISTALLINES DE N-[4- (CHLORODIFLUOROMÉTHOXY) PHÉNYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE (CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 7995
Patent: צורות גבישיות של n-[4-(כלורודיפלואורומתוקסי)פניל]-6-[(r3)-3-הידרוקסיפירולידין-1-יל]-5-(h1-פירזול-5-יל)פירידין-3-קרבוקסמיד (Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 22532404
Patent: Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３Ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１Ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 21013970
Patent: FORMAS CRISTALINAS DE N-[4-(CLORODIFLUOROMETOXI)FENIL]-6-[(3R)-3-H IDROXIPIRROLIDIN-1-IL]-5-(1H-PIRAZOL-5-IL)PIRIDINA-3-CARBOXAMIDA. (CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)- 3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAM IDE.)
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 220009414
Patent: N-[4-페닐]-6-[(3R)-3-히드록시피롤리딘-1-일]-5-(1H-피라졸-5-일)피리딘-3-카복사미드의 결정질 형태
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 2110823
Patent: Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SCEMBLIX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Colombia | 7131380 | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | ⤷ Sign Up |
| Brazil | 112021022712 | Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida | ⤷ Sign Up |
| Australia | 2013261130 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | ⤷ Sign Up |
| European Patent Office | 3969117 | FORMES CRISTALLINES DE N-[4- (CHLORODIFLUOROMÉTHOXY) PHÉNYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE (CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE) | ⤷ Sign Up |
| Philippines | 12014502531 | BENZAMINE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ⤷ Sign Up |
| China | 104302638 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SCEMBLIX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2861579 | 2022C/548 | Belgium | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, ZOALS ASCIMINIB HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1670 20220826 |
| 2861579 | 22C1053 | France | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TEL QUE LE CHLORHYDRATE D'ASCIMINIB; REGISTRATION NO/DATE: EU/1/22/1670 20220826 |
| 2861579 | PA2022523 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ASCIMINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TOKIA KAIP ASCIMINIBO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/22/1670 20220825 |
| 2861579 | C202230056 | Spain | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, TAL COMO HIDROCLORURO DE ASCIMINIB; NATIONAL AUTHORISATION NUMBER: EU/1/22/1670; DATE OF AUTHORISATION: 20220825; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1670; DATE OF FIRST AUTHORISATION IN EEA: 20220825 |
| 2861579 | 45/2022 | Austria | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, WIE ASCIMINIB-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1670 (MITTEILUNG) 20220826 |
| 2861579 | C20220039 00385 | Estonia | ⤷ Sign Up | PRODUCT NAME: ASTSIMINIIB;REG NO/DATE: EU/1/22/1670 26.08.2022 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
